INOVIQ Limited completed the share purchase plan

INOVIQ Limited (ASX: IIQ) announced the successful completion of the share purchase plan that was announced on 12 June 2024. The SPP received applications totaling AU$2.379 million, exceeding the initial target of AU$2 million. The company had the discretion to accept oversubscriptions of up to AU$0.4 million in addition to the initial AU$2 million target, which was the company's maximum placement capacity.

The company will use these funds to advance the commercialization of EXO-NET research tools and SubB2M breast and ovarian cancer monitoring tests, further the development of pipeline diagnostics, and expedite research of high-value cancer therapeutics.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com